AbbVie Inc. $ABBV Stake Raised by Tyche Wealth Partners LLC

Tyche Wealth Partners LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 14.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,447 shares of the company’s stock after acquiring an additional 2,470 shares during the period. Tyche Wealth Partners LLC’s holdings in AbbVie were worth $4,443,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Chelsea Counsel Co. purchased a new stake in AbbVie in the 3rd quarter worth about $26,000. Westend Capital Management LLC purchased a new stake in AbbVie in the 4th quarter worth about $29,000. Texas Capital Bancshares Inc TX purchased a new stake in AbbVie in the 3rd quarter worth about $31,000. Evolution Wealth Management Inc. purchased a new stake in AbbVie in the 2nd quarter worth about $26,000. Finally, Caitlin John LLC purchased a new stake in AbbVie in the 3rd quarter worth about $33,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Late?breaking Phase 2 data for mirvetuximab soravtansine?gynx (ELAHERE) in platinum?sensitive ovarian cancer showed strong activity (objective response rate ~62.7% in FR? ?50% patients) with consistent safety, supporting broader use across the ovarian cancer continuum and raising upside for AbbVie’s oncology franchise. AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story
• Positive Sentiment: AbbVie struck an exclusive global license (ex-China/HK/Macau) with Haisco for two acute pain assets in a deal reported as up to roughly $715–745M, adding late?stage pain programs and diversifying AbbVie’s pipeline outside its core immunology and oncology businesses. Haisco’s shares reacted positively. AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
• Positive Sentiment: An analyst raised AbbVie’s price target to $249, signaling bullish analyst sentiment that could support upside if execution on new indications and the pain franchise continues. AbbVie (NYSE:ABBV) Price Target Raised to $249.00
• Neutral Sentiment: Coverage notes (Zacks) flag neuroscience (Botox, Vraylar) as a growth driver for Q1 revenue, which could help offset legacy product declines but is already anticipated by the Street. Will AbbVie’s Neuroscience Franchise Aid Top-line Growth in Q1?
• Neutral Sentiment: Local reporting on an AbbVie Foundation donation to a university cancer center says the gift won’t affect clinical independence — largely a reputational/PR item rather than a financial driver. UCMed Administrators Say AbbVie Foundation Donation to New Cancer Center Will Not Infringe on Its Independence
• Negative Sentiment: Despite the positive data and deal news, the stock is trading lower—likely reflecting short?term profit?taking, stretched valuation (high P/E vs. peers) and technical pressure (shares below recent 50/200?day moving averages), which can mute immediate upside. (Background market/technical context provided.)

AbbVie Price Performance

Shares of ABBV stock opened at $206.40 on Tuesday. AbbVie Inc. has a fifty-two week low of $168.54 and a fifty-two week high of $244.81. The stock’s 50-day moving average is $219.96 and its two-hundred day moving average is $223.96. The firm has a market cap of $364.94 billion, a P/E ratio of 87.46, a PEG ratio of 0.75 and a beta of 0.38.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period in the prior year, the firm posted $2.16 EPS. The business’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Insider Activity at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.06% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ABBV shares. Cantor Fitzgerald reduced their price objective on AbbVie from $250.00 to $240.00 and set an “overweight” rating for the company in a research note on Wednesday, April 8th. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Royal Bank Of Canada assumed coverage on AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price on the stock. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Piper Sandler upped their target price on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $253.00.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.